Text Size

Glaucomatous optic neuropathy treatment options: The promise of novel therapeutics, techniques and tools to help preserve vision

Sharif N.


  • 2018
  • Neural Regeneration Research
View publication
  • Therapeutic Area

    Glaucoma

  • Technology

    Drug Delivery

  • Categories

    Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

  • Affiliations

    Department of Global Alliances and External Research, Global Ophthalmology Research and Development, Santen Incorporated, Emeryville, CA, United States; Department of Pharmaceutical Sciences, Texas Southern University, Houston, TX, United States; Department of Pharmacology and Neuroscience, University of North Texas Health Sciences Center, Fort Worth, TX, United States; Department of Pharmacy Sciences, Creighton University, Omaha, NE, United States; Department of Surgery and Cancer, Imperial College of Science and Technology, St. Mary's Campus, London, United Kingdom

Related Publications

IDrugs and idevices discovery research: Preclinical assays, techniques, and animal model studies for ocular hypotensives and neuroprotectants

Sharif N.A.


Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.


Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022